Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator

Autores
Gerometta, Rosana María del Rosario; Kumar, Sandeep; Shah, Shaily; Alvarez, Larry; Candia, Oscar; Danias, John
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model. METHODS. Three animal groups were subjected to bilateral steroid-induced IOP elevation using thrice daily topical ocular prednisolone administration. In the first group (N ¼ 8), one eye each of two sheep was injected intravitreally with 100 lg, 200 lg, 500 lg, or 1 mg human recombinant tPA, while contralateral eyes received vehicle. In the second group (N ¼ 2), one eye was injected intravitreally with tPA (100 lg), while contralateral eyes received vehicle containing L-arginine. In the third group (N ¼ 4), each animal received intravitreal tPA in one eye concurrently with initiation of bilateral steroid administration. IOP was monitored for the duration of the experiment. Tissues from eyes of the third group were used to determine relative gene expression. RESULTS. In the first and second groups, IOP decreased by 9.7 (62.8) and 9.7 (61.6) mm Hg, respectively, 24 hours after tPA administration. In the third group, tPA-treated eyes did not develop IOP elevation with DIOP of 11.8 (61.3) mm Hg 8 days later. In all tPA-treated eyes, IOP remained low until the end of the study. mRNA levels in the trabecular meshwork were decreased for plasminogen activator tissue (PLAT), increased for matrix-metalloproteinase 1 (MMP-1), and stable for plasminogen activator inhibitor 1 (PAI-1), MMP-2, MMP-9, and MMP- 13 in tPA-treated eyes compared with contralateral controls. PAI-1 mRNA levels in ciliary processes also remained similar. CONCLUSIONS. Recombinant human tPA is effective in both preventing and reversing steroidinduced IOP elevation in sheep. Tissue plasminogen activator may be useful as a therapeutic agent in steroid-induced glaucoma.
Fil: Gerometta, Rosana María del Rosario. University Of New York; Estados Unidos. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Kumar, Sandeep. State University Of New York; Estados Unidos
Fil: Shah, Shaily. State University Of New York; Estados Unidos
Fil: Alvarez, Larry. State University Of New York; Estados Unidos
Fil: Candia, Oscar. State University Of New York; Estados Unidos
Fil: Danias, John. State University Of New York; Estados Unidos
Materia
INTRAOCULAR PRESSURE
TISSUE PLASMINOGEN ACTIVATOR
TRABECULAR MESHWORK
EXTRACELLULAR MATRIX
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/8564

id CONICETDig_3909d4e7da81b5e294b26f2af0db9fce
oai_identifier_str oai:ri.conicet.gov.ar:11336/8564
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen ActivatorGerometta, Rosana María del RosarioKumar, SandeepShah, ShailyAlvarez, LarryCandia, OscarDanias, JohnINTRAOCULAR PRESSURETISSUE PLASMINOGEN ACTIVATORTRABECULAR MESHWORKEXTRACELLULAR MATRIXhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model. METHODS. Three animal groups were subjected to bilateral steroid-induced IOP elevation using thrice daily topical ocular prednisolone administration. In the first group (N ¼ 8), one eye each of two sheep was injected intravitreally with 100 lg, 200 lg, 500 lg, or 1 mg human recombinant tPA, while contralateral eyes received vehicle. In the second group (N ¼ 2), one eye was injected intravitreally with tPA (100 lg), while contralateral eyes received vehicle containing L-arginine. In the third group (N ¼ 4), each animal received intravitreal tPA in one eye concurrently with initiation of bilateral steroid administration. IOP was monitored for the duration of the experiment. Tissues from eyes of the third group were used to determine relative gene expression. RESULTS. In the first and second groups, IOP decreased by 9.7 (62.8) and 9.7 (61.6) mm Hg, respectively, 24 hours after tPA administration. In the third group, tPA-treated eyes did not develop IOP elevation with DIOP of 11.8 (61.3) mm Hg 8 days later. In all tPA-treated eyes, IOP remained low until the end of the study. mRNA levels in the trabecular meshwork were decreased for plasminogen activator tissue (PLAT), increased for matrix-metalloproteinase 1 (MMP-1), and stable for plasminogen activator inhibitor 1 (PAI-1), MMP-2, MMP-9, and MMP- 13 in tPA-treated eyes compared with contralateral controls. PAI-1 mRNA levels in ciliary processes also remained similar. CONCLUSIONS. Recombinant human tPA is effective in both preventing and reversing steroidinduced IOP elevation in sheep. Tissue plasminogen activator may be useful as a therapeutic agent in steroid-induced glaucoma.Fil: Gerometta, Rosana María del Rosario. University Of New York; Estados Unidos. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Kumar, Sandeep. State University Of New York; Estados UnidosFil: Shah, Shaily. State University Of New York; Estados UnidosFil: Alvarez, Larry. State University Of New York; Estados UnidosFil: Candia, Oscar. State University Of New York; Estados UnidosFil: Danias, John. State University Of New York; Estados UnidosAssociation For Research In Vision And Ophthalmology2013-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/8564Gerometta, Rosana María del Rosario; Kumar, Sandeep; Shah, Shaily; Alvarez, Larry; Candia, Oscar; et al.; Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator; Association For Research In Vision And Ophthalmology; Investigative Ophthalmology & Visual Science; 54; 12-2013; 7903-79090146-04041552-5783enginfo:eu-repo/semantics/altIdentifier/doi/10.1167/iovs.13-12801info:eu-repo/semantics/altIdentifier/url/http://iovs.arvojournals.org/article.aspx?articleid=2127542info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:36Zoai:ri.conicet.gov.ar:11336/8564instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:36.907CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
title Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
spellingShingle Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
Gerometta, Rosana María del Rosario
INTRAOCULAR PRESSURE
TISSUE PLASMINOGEN ACTIVATOR
TRABECULAR MESHWORK
EXTRACELLULAR MATRIX
title_short Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
title_full Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
title_fullStr Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
title_full_unstemmed Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
title_sort Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator
dc.creator.none.fl_str_mv Gerometta, Rosana María del Rosario
Kumar, Sandeep
Shah, Shaily
Alvarez, Larry
Candia, Oscar
Danias, John
author Gerometta, Rosana María del Rosario
author_facet Gerometta, Rosana María del Rosario
Kumar, Sandeep
Shah, Shaily
Alvarez, Larry
Candia, Oscar
Danias, John
author_role author
author2 Kumar, Sandeep
Shah, Shaily
Alvarez, Larry
Candia, Oscar
Danias, John
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv INTRAOCULAR PRESSURE
TISSUE PLASMINOGEN ACTIVATOR
TRABECULAR MESHWORK
EXTRACELLULAR MATRIX
topic INTRAOCULAR PRESSURE
TISSUE PLASMINOGEN ACTIVATOR
TRABECULAR MESHWORK
EXTRACELLULAR MATRIX
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model. METHODS. Three animal groups were subjected to bilateral steroid-induced IOP elevation using thrice daily topical ocular prednisolone administration. In the first group (N ¼ 8), one eye each of two sheep was injected intravitreally with 100 lg, 200 lg, 500 lg, or 1 mg human recombinant tPA, while contralateral eyes received vehicle. In the second group (N ¼ 2), one eye was injected intravitreally with tPA (100 lg), while contralateral eyes received vehicle containing L-arginine. In the third group (N ¼ 4), each animal received intravitreal tPA in one eye concurrently with initiation of bilateral steroid administration. IOP was monitored for the duration of the experiment. Tissues from eyes of the third group were used to determine relative gene expression. RESULTS. In the first and second groups, IOP decreased by 9.7 (62.8) and 9.7 (61.6) mm Hg, respectively, 24 hours after tPA administration. In the third group, tPA-treated eyes did not develop IOP elevation with DIOP of 11.8 (61.3) mm Hg 8 days later. In all tPA-treated eyes, IOP remained low until the end of the study. mRNA levels in the trabecular meshwork were decreased for plasminogen activator tissue (PLAT), increased for matrix-metalloproteinase 1 (MMP-1), and stable for plasminogen activator inhibitor 1 (PAI-1), MMP-2, MMP-9, and MMP- 13 in tPA-treated eyes compared with contralateral controls. PAI-1 mRNA levels in ciliary processes also remained similar. CONCLUSIONS. Recombinant human tPA is effective in both preventing and reversing steroidinduced IOP elevation in sheep. Tissue plasminogen activator may be useful as a therapeutic agent in steroid-induced glaucoma.
Fil: Gerometta, Rosana María del Rosario. University Of New York; Estados Unidos. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Kumar, Sandeep. State University Of New York; Estados Unidos
Fil: Shah, Shaily. State University Of New York; Estados Unidos
Fil: Alvarez, Larry. State University Of New York; Estados Unidos
Fil: Candia, Oscar. State University Of New York; Estados Unidos
Fil: Danias, John. State University Of New York; Estados Unidos
description PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model. METHODS. Three animal groups were subjected to bilateral steroid-induced IOP elevation using thrice daily topical ocular prednisolone administration. In the first group (N ¼ 8), one eye each of two sheep was injected intravitreally with 100 lg, 200 lg, 500 lg, or 1 mg human recombinant tPA, while contralateral eyes received vehicle. In the second group (N ¼ 2), one eye was injected intravitreally with tPA (100 lg), while contralateral eyes received vehicle containing L-arginine. In the third group (N ¼ 4), each animal received intravitreal tPA in one eye concurrently with initiation of bilateral steroid administration. IOP was monitored for the duration of the experiment. Tissues from eyes of the third group were used to determine relative gene expression. RESULTS. In the first and second groups, IOP decreased by 9.7 (62.8) and 9.7 (61.6) mm Hg, respectively, 24 hours after tPA administration. In the third group, tPA-treated eyes did not develop IOP elevation with DIOP of 11.8 (61.3) mm Hg 8 days later. In all tPA-treated eyes, IOP remained low until the end of the study. mRNA levels in the trabecular meshwork were decreased for plasminogen activator tissue (PLAT), increased for matrix-metalloproteinase 1 (MMP-1), and stable for plasminogen activator inhibitor 1 (PAI-1), MMP-2, MMP-9, and MMP- 13 in tPA-treated eyes compared with contralateral controls. PAI-1 mRNA levels in ciliary processes also remained similar. CONCLUSIONS. Recombinant human tPA is effective in both preventing and reversing steroidinduced IOP elevation in sheep. Tissue plasminogen activator may be useful as a therapeutic agent in steroid-induced glaucoma.
publishDate 2013
dc.date.none.fl_str_mv 2013-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/8564
Gerometta, Rosana María del Rosario; Kumar, Sandeep; Shah, Shaily; Alvarez, Larry; Candia, Oscar; et al.; Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator; Association For Research In Vision And Ophthalmology; Investigative Ophthalmology & Visual Science; 54; 12-2013; 7903-7909
0146-0404
1552-5783
url http://hdl.handle.net/11336/8564
identifier_str_mv Gerometta, Rosana María del Rosario; Kumar, Sandeep; Shah, Shaily; Alvarez, Larry; Candia, Oscar; et al.; Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator; Association For Research In Vision And Ophthalmology; Investigative Ophthalmology & Visual Science; 54; 12-2013; 7903-7909
0146-0404
1552-5783
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1167/iovs.13-12801
info:eu-repo/semantics/altIdentifier/url/http://iovs.arvojournals.org/article.aspx?articleid=2127542
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Association For Research In Vision And Ophthalmology
publisher.none.fl_str_mv Association For Research In Vision And Ophthalmology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269648622452736
score 13.13397